Renal ontogeny of ifosfamide nephrotoxicity

被引:26
作者
Aleksa, K
Halachmi, N
Ito, S
Koren, G
机构
[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON, Canada
来源
JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 2004年 / 144卷 / 06期
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.lab.2004.09.002
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Ifosfamide-induced nephrotoxicity adversely affects the health and well-being of children with cancer. We have recently shown age-dependent nephrotoxicity induced by ifosfamide, with younger children (<3 years) substantially more vulnerable. The mechanisms leading to this age-related ifosfamide-induced renal damage have not been identified. Underlying this work is the hypothesis that renal ontogeny is involved in the expression and activity of the cytochrome P450 (CYP) enzymes responsible for IF metabolism to the nephrotoxic chloroacetaldehyde. We evaluated renal CYP3A and 2B22 activity in pigs between the ages of 1 day and adulthood, as well as the metabolism of ifosfamide by renal microsomes to 2- and 3-dechloroethylifosfamide (2-DCEIF and 3-DCEIF, respectively). Kidney CYP3A messenger RNA expression peaked 15 to 60 days (0.7-76 +/- 0.19 CYP3A/actin ratio; P < 0.001). Subsequently, this level decreased to adult values (0.54 - 0.03 CYP3A/actin ratio; P = 0.04). Similarly, we detected an increase in the ifosfamide-metabolism rate between young (18 +/- 2 pmol/mg protein/ min) and adult (12.2 +/- 0.17 pmol/mg protein/min) animals (P = 0.002). Ours is the first documentation of ontogeny of renal CYP3A and of renal ifosfamide metabolism. These data suggest that age-dependent ifosfamide nephrotoxicity is, at least in part, due to ontogeny in the production chloroacetaldehyde.
引用
收藏
页码:285 / 293
页数:9
相关论文
共 51 条
[1]   Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: Pharmacokinetic modeling for estimation of intracellular levels [J].
Aleksa, K ;
Ito, S ;
Koren, G .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 143 (03) :159-162
[2]  
Anzenbacher P, 1998, DRUG METAB DISPOS, V26, P56
[3]  
ARNDT C, 1994, CANCER CHEMOTH PHARM, V34, P431, DOI 10.1007/s002800050166
[4]   CHROMATOGRAPHIC RESOLUTIONS .14. OPTICAL RESOLUTION OF THE RACEMIC ANTICANCER DRUG IFOSFAMIDE AND OTHER CHIRAL OXAZAPHOSPHORINES [J].
BLASCHKE, G ;
MAIBAUM, J .
JOURNAL OF CHROMATOGRAPHY, 1986, 366 :329-334
[5]   RAPID METHOD FOR THE DETERMINATION OF IFOSFAMIDE AND CYCLOPHOSPHAMIDE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH SOLID-PHASE EXTRACTION [J].
BURTON, LC ;
JAMES, CA .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 431 (02) :450-454
[6]  
CHANG TKH, 1993, CANCER RES, V53, P5629
[7]  
Code EL, 1997, DRUG METAB DISPOS, V25, P985
[8]  
DESCHEPPER J, 1993, ACTA PAEDIATR, V82, P373
[9]  
Domanski TL, 1999, J PHARMACOL EXP THER, V290, P1141
[10]   A DISCONTINUOUS AND HIGHLY POROUS SODIUM DODECYL SULFATE-POLYACRYLAMIDE SLAB GEL SYSTEM OF HIGH-RESOLUTION [J].
DOUCET, JP ;
TRIFARO, JM .
ANALYTICAL BIOCHEMISTRY, 1988, 168 (02) :265-271